Drug intelligence / Profile preview

EXP-LP

Development stage: Unknown
Lead developer: Eximore
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Ophthalmic

Overview

EXP-LP is a non-degradable punctal plug designed for ophthalmic use, specifically to provide sustained release of latanoprost directly to the eye. Latanoprost is a first-line prostaglandin analog used primarily in the treatment of glaucoma and ocular hypertension. The device utilizes Eximore’s proprietary “pack & release” nano-layered drug delivery platform, which enables effective and prolonged administration of medication for chronic eye conditions such as glaucoma and dry eye syndrome[1].

Brand names: EXP-LP
Other names: EXP-LP

Targets

PTGFR (Prostaglandin F2 alpha receptor)

Beyond the preview

Go deeper on EXP-LP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EXP-LP.

Explore the full profile